Response to dextran in posthemorrhagic shock after combined adrenergic receptor blockade.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001158:Arteries; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output; D003911:Dextrans / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D004357:Drug Synergism; D005263:Femoral Artery / Q000503:physiopathology; D006400:Hematocrit; D007275:Injections, Intravenous; D010313:Partial Pressure; D010643:Phenoxybenzamine / Q000494:pharmacology / Q000627:therapeutic use*; D010953:Plasma Volume / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D012771:Shock, Hemorrhagic / Q000188:drug therapy*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects; D014667:Vasopressins / Q000494:pharmacology; D014690:Venous Pressure / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D003911:Dextrans; D010643:Phenoxybenzamine; D014667:Vasopressins; D002245:Carbon Dioxide; D011433:Propranolol